News | September 23, 2024
DevCo completes strategic capital raise for investment in Medix Biochemica
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Subscribe To Our Newsletter & Stay Updated
